Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic
Frontline Gastroenterol
.
2021 May 27;13(1):89-90.
doi: 10.1136/flgastro-2020-101760.
eCollection 2022.
Authors
John McGoran
1
,
Alan Wilson
2
,
Shannan McErlain
2
,
Noreen Kennedy
1
,
Caroline Masterson
1
,
Caroline Collins
1
,
Graham Morrison
1
Affiliations
1
Gastroenterology, Belfast Health and Social Care Trust, Belfast, UK.
2
Pharmacy, Belfast Health and Social Care Trust, Belfast, UK.
PMID:
34966537
PMCID:
PMC8666859
DOI:
10.1136/flgastro-2020-101760
No abstract available
Keywords:
COVID-19; inflammatory bowel disease.